HIGHLIGHT
Zinforo

Zinforo Dosage/Direction for Use

ceftaroline fosamil

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Full Prescribing Info
Dosage/Direction for Use
Dosage in adults and paediatric patients: The recommended dosage of ceftaroline fosamil is 600 mg administered every 12 hours by intravenous infusion over 5 to 60 minutes (standard dose), with appropriate reductions for paediatric patients (see Table 10). The duration of treatment should be guided by the type of infection to be treated, its severity, and the patient's clinical response.
For the treatment of cSSTI confirmed or suspected to be caused by Staphylococcus aureus (S. aureus) with a Minimum Inhibitory Concentration (MIC) <2 mg/L to ceftaroline, the dose of ceftaroline fosamil is 600 mg administered every 12 hours by intravenous infusion over 5 to 60 minutes (standard dose), with appropriate reductions for paediatric patients (see Table 10).
For the treatment of patients with cSSTI confirmed or suspected to be caused by S. aureus with an MIC = 2 mg/L to 4 mg/L to ceftaroline, the dose of ceftaroline fosamil is 600 mg administered every 8 hours by intravenous infusion over 120 minutes (high dose), with appropriate reductions for paediatric patients (see Table 10).

Click on icon to see table/diagram/image

Special populations: Patients with renal impairment: The dose should be adjusted when creatinine clearance (CrCL) is ≤50 mL/min, as shown in Table 11. Dose recommendations for children and adolescents are based on PK modelling. End Stage Renal Disease (ESRD) patients can only be dosed as in Table 11.
For ESRD, there is insufficient information to recommend dosage adjustments in adolescents aged from 12 to <18 years with bodyweight <33 kg and in children aged from 2 to 12 years. There is insufficient information to recommend dosage adjustments in paediatric patients <2 years with moderate or severe renal impairment or ESRD. (See Table 11.)

Click on icon to see table/diagram/image

Patients with hepatic impairment: No dosage adjustment is considered necessary in patients with hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Elderly patients: No dosage adjustment is required for the elderly with creatinine clearance (CrCL) values >50 mL/min (see Pharmacology: Pharmacokinetics under Actions).
Reconstitution and compatibility: See Special precautions for disposal and other handling under Cautions for Usage.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in